Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

Inclusion Criteria: * Age greater than or equal to 60 years old * Current Major Depressive Episode or Current Depressive Disorder Not Otherwise Specified or Dysthymic Disorder * Montgomery-Asberg Depression Rating Scale (MADRS) greater than or equal to 12 * Modified Mini-Mental State (3MS) score greater than or equal to 84 * MoCA-BLIND greater than or equal to 13 Exclusion Criteria: * History of Mania or Psychosis * Current suicidal ideation that cannot be safely managed within the confines of a clinical trial * Alcohol or Substance Abuse (current or past 3 months) endorsed via phone screening interview or diagnosed by Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID) * Dementia of any etiology endorsed via phone screening interview or diagnosed by SCID * Medical conditions with known significant effects on mood (e.g., stroke, current hypothyroid state) as well as unstable medical illness, including delirium, uncontrolled diabetes mellitus, hypertension, hyperlipidemia, or cardiovascular risk factors that are not under medical management Unwilling or clinically determined to be unable to taper from high doses of benzodiazepines (equivalent to \> 2 mg lorazepam/day) or other anti-depressant/anti-anxiety medications at time of screening. However, for participants who are prescribed low dose psychotropics for pain, sleep disturbances, and/or medical conditions (e.g. amitriptyline for peripheral neuropathy, low dose trazodone a…